(pyridine-2-sulfonyl)-acetic acid methyl ester | 865706-15-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (pyridine-2-sulfonyl)-acetic acid methyl ester
• 英文别名: Methyl 2-pyridin-2-ylsulfonylacetate
• CAS: 865706-15-6
• 化学式: C₈H₉NO₄S
• 分子量: 215.23
• InChiKey: JPNXOIHAIZIKMJ-UHFFFAOYSA-N

物化性质

• 沸点：
  406.8±41.0 °C(Predicted)
• 密度：
  1.337±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (pyridine-2-sulfonyl)-acetic acid methyl ester 在 (2S)-2-[二苯基[(三甲基硅酯)氧基]甲基]-吡咯烷 、 sodium tetrahydroborate 、 三乙酰氧基硼氢化钠 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 55.0h， 生成 1-isobutyl-4-phenyl-3-(pyridine-2-sulfonyl)-piperidin-2-one
  参考文献：
  名称：

  通过新的羰基甲基2-吡啶基砜的有机催化高对映选择性共轭加成到烯醛上，合成3-取代的1，5-醛酯。

  摘要：

  已经开发出高收率和高对映选择性的高度对映选择性的有机催化方案，该方案用于将新的亲核羰基甲基2-吡啶基砜共轭添加到烯醛中。所得的迈克尔加合物是用于各种有机转化的多功能构建基块。

  DOI：

  10.1039/c1cc15714k

文献信息

• [EN] TETRAHYDROCARBAZOLES AND DERIVATIVES<br/>[FR] TETRAHYDROCARBAZOLES ET DERIVES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005092856A1

  公开（公告）日：2005-10-06

  The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRß agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在描述和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物对于治疗和预防由LXRα和/或LXRß激动剂调节的疾病是有用的，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇、高LDL-胆固醇、动脉粥样硬化疾病、糖尿病，特别是非胰岛素依赖型糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病如结肠炎、胰腺炎、肝胆瘀积/肝纤维化，以及具有炎症成分的疾病，如阿尔茨海默病或认知功能受损/可改善的疾病。
• Tetrahydrocarbazoles and derivatives
  申请人：Dehmlow Henrietta

  公开号：US20050215577A1

  公开（公告）日：2005-09-29

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求中有定义，并且其药学上可接受的盐和/或药学上可接受的酯。这些化合物在LXRα和/或LXRβ激动剂调节的疾病的治疗和预防中有用，包括增加的脂质和胆固醇水平，特别是低HDL-胆固醇，高LDL-胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，脂质代谢异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化和具有炎症成分的疾病，如阿尔茨海默病或受损/可改善的认知功能。
• TETRAHYDROCARBAZOLES AND DERIVATIVES
  申请人：Dehmlow Henrietta

  公开号：US20100216833A1

  公开（公告）日：2010-08-26

  The present invention relates to compounds of the formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , X 2 , X 3 , X 4 , n, and k are defined in the description and claims, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and/or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis/fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired/improvable cognitive function.

  本发明涉及式（I）的化合物，其中R1、R2、R3、R4、R5、X1、X2、X3、X4、n和k在说明书和权利要求书中定义，并且其药学上可接受的盐和/或药学上可接受的酯。该化合物用于治疗和预防LXRα和/或LXRβ激动剂调节的疾病，包括增加的脂质和胆固醇水平，特别是低HDL胆固醇，高LDL胆固醇，动脉粥样硬化疾病，糖尿病，特别是非胰岛素依赖性糖尿病，代谢综合征，血脂异常，阿尔茨海默病，败血症，炎症性疾病，如结肠炎，胰腺炎，肝胆瘤/纤维化以及有炎症成分的疾病，例如阿尔茨海默病或受损/可改善的认知功能。
• A free-radical design featuring an intramolecular migration for a synthetically versatile alkyl–(hetero)arylation of simple olefins
  作者：Dylan J. Babcock、Andrew J. Wolfram、Jaxon L. Barney、Santino M. Servagno、Ayush Sharma、Eric D. Nacsa

  DOI：10.1039/d3sc06476j

  日期：2024.3.13

  A free-radical approach has enabled the development of a synthetically versatile alkyl–(hetero)arylation of olefins. Alkyl and (hetero)aryl groups were added concurrently to a full suite of mono- to tetrasubstituted simple alkenes (i.e., without requiring directing or electronically activating groups) for the first time. Key advances also included the introduction of synthetically diversifiable alkyl

  自由基方法使得合成多功能的烯烃烷基（杂）芳基化得以发展。首次将烷基和(杂)芳基同时添加到全套单取代至四取代的简单烯烃中(即，不需要定向基团或电子活化基团)。关键进展还包括引入具有不同取代度的合成多样化烷基、在环状和无环环境中良好的非对映控制、添加具有路易斯碱性氮原子以及简单苯的具有生物价值的杂芳烃，以及生成叔或季苄基中心。这一转变的合成潜力通过利用它作为 oliceridine 简洁合成的关键步骤得到了证明，oliceridine 是一种新型止痛药，于 2020 年获得 FDA 批准。
• Discovery of tetrahydro-cyclopenta[b]indole as selective LXRs modulator
  作者：Hassen Ratni、Denise Blum-Kaelin、Henrietta Dehmlow、Peter Hartman、Philippe Jablonski、Raffaello Masciadri、Cyrille Maugeais、Angelique Patiny-Adam、Narendra Panday、Matthew Wright

  DOI：10.1016/j.bmcl.2009.01.109

  日期：2009.3

  A series of tetrahydro-cyclopenta[b] indoles modulating the activity of the liver-X-receptor (LXR) were derived from a high throughput screening hit. The potency and selectivity for LXR beta versus LXR alpha was improved. One compound, administered to wild-type mice modestly increased plasma HDL-cholesterol with no change in plasma triglycerides (TG) and reduced effects on liver TG content compared to T0901317. This novel series of LXR agonists shows promise to improve therapeutic efficacy with reduced potential to increase TG. (C) 2009 Elsevier Ltd. All rights reserved.